Acute respiratory diseases: progression features, pharmaceutical therapy
https://doi.org/10.21518/2079-701X-2018-15-82-88
Abstract
Acute respiratory diseases (ARD) are widespread diseases and are of great social importance. Diagnosis of acute respiratory infections implies the damage to the respiratory system caused by a wide range of pathogens. Among the pathogens of acute respiratory infections are viruses of acute respiratory viral infection (ARVI) group, including influenza, as well as fungal and bacterial pathogens, which include intracellular bacteria: mycoplasma and chlamydia. Diseases caused by intracellular pathogens are treated by antibacterial drugs that can easily penetrate the cells and create there high concentrations.
About the Authors
N. V. Orlova
Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Health of Russia
Russian Federation
Russian Federation
T. G. Suranova
Institute for Advanced Training of FMBA of Russia
Russian Federation
Russian Federation
References
1. Clinical protocol for diagnosis and treatment of acute respiratory viral infections and flu in adults (primary health care). Approved by the minutes of the meeting of the Expert Commission on Health Development of the Ministry of Health of the Russian Federation No. 18 of September 19, 2013.
2. Acute respiratory viral infections in adults: clinical guidelines:. Considered and recommended for approval by the relevant commission of the Ministry of Health of Russia specializing in «infectious diseases» at meetings on March 25, 2014 and October 8, 2014. 69 p.
3. Nikiforov VV, Kolobukhina LV, Suranova TG et al. Influenza and acute respiratory viral infections: modern rational etiotropic and pathogenetic therapy. Algorithms for rendering medical care to patients. Method. recommendations. M.: Spetskniga, 2018. 24 p.
4. Vasin AV, Sologub TV. Influenza in adults: diagnosis, treatment, techniques and methods of nonspecific prevention. Methodical recommendations. SPb., 2016. 82 p.
5. Influenza in adults. Guidelines of the Ministry of Health of the Russian Federation in 2017. Prepared by the International Association of Specialists in Infectious Diseases (IASI), a non-profit organization.
6. Simon HB. Bacterial infections of the upper respiratory tract. ACP Medicine. 2010.
7. Carbon C, Hotton JM, Pepin LF et al. Economic analysis of antibiotic regimens used in the treatment pharyngitis: a prospective comparison of azithromycin versus roxithromycin. J Antimicrob Chemother, 1996, 37(suppl. C): 151– 161.
8. Chatzimanolis E, Marsan N, Lefatzis D et al. Comparison of roxithromycin with co-amoxiclav in patients with sinusitis. J Antimicrob Chemother, 1998, 41(suppl. B): 81–84.
9. DeCampora E, Camaioni A, Leonardi M et al. Comparative efficacy and safety of roxithromycin and clarithromycin in upper respiratory tract infections. Diagn Microbiol Infect Dis, 1992, 15(suppl. 4): 119S–1122S.
10. Nagino K, Kobayashi H. Influence of macrolideson mucoid alginate biosynthetic enzyme from. Clin Microbiol Infect, 1997, 3: 432–39.
11. De Vlieger A, Druart M, Puttemans M. Roxithromycin versus doxycycline in the treatment of acute exacerbations of chronic bronchitis. Diagn Microbiol Infect Dis, 1992, 15(suppl. 4): 123S–127S.
12. Veselov AV. Clinico-pharmacological aspects of using of roxithromycin in practice. Pharmateca, 2006, 1: 34-36.
Review
For citations:
Orlova NV, Suranova TG. Acute respiratory diseases: progression features, pharmaceutical therapy. Meditsinskiy sovet = Medical Council. 2018;(15):82-88. (In Russ.) https://doi.org/10.21518/2079-701X-2018-15-82-88
Views:
1045
Email this article 